Ken H. Young
University of North Carolina at Chapel Hill(US)Cincinnati Children's Hospital Medical Center(US)Duke University(US)Durham University(GB)Clinical Research Institute(US)Duke Institute for Health Innovation(US)Duke Medical Center(US)Royal Surrey NHS Foundation Trust(GB)Duke University Hospital(US)Duke Cancer InstituteUniversity of Cincinnati Medical Center(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Viral-associated cancers and disorders, Immune Cell Function and Interaction
Most-Cited Works
- → Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone(2012)679 cited
- → MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program(2013)672 cited
- → Diffuse large B-cell lymphoma(2017)617 cited
- → PD-1 expression and clinical PD-1 blockade in B-cell lymphomas(2017)425 cited
- → Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma(2015)417 cited
- → Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients